Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nilotinib study in inoperable PVNS/TGCT
2010-018869-29Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in tenosynovial giant cell tumor (TGCT), sponsored by Centre Léon Bérard. Primary endpoint: Non-progression rate at 12 weeks. Started Jun 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on 2010-018869-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018869-29.